A REVIEW ADVERSE DRUG REACTIONS: MECHANISMS, MANAGEMENT, AND MITIGATION

Pankaj Pratap Sanap, Prashant Shivaji Narode, Amit Sukhdev Ghule, Mangesh Nandkishor Dhone
Gajanan Maharaj College Of Pharmacy, Chh. Sambhajinagar
pankajsanap00@gmail.com
PROF. TOOBA KHAN (M.pharm) Department Of Pharmaceutics
DR. KAVITA KULKARNI (Phd.Mpharm) Department Of Quality Assurance, Gajanan Maharaj College Of Pharmacy, Chh.Sambhajinaga.

Abstract

A drug is a single active chemical used in medicines for diagnosing, preventing, and treating diseases. Sometimes, drugs can cause adverse reactions, which are unexpected effects that can harm patients and lead to serious health issues. These adverse drug reactions (ADRs) can contribute significantly to illness and even death, particularly in hospitalized patients.

Many ADRs can be prevented, often due to prescription errors, while others may be unavoidable and only become apparent after a drug is on the market. The occurrence of ADRs often relates to the drug's pharmacology and can show a dose-response relationship in susceptible individuals.

ADRs can be classified into two main types:

- ***Type A reactions** are common and predictable, occurring in anyone.*
- ***Type B reactions** are rare and unpredictable, affecting only those with specific vulnerabilities.*

Variability in how patients respond to medications can be influenced by differences in drug concentrations in the body, which is where pharmacogenomics comes in. This field studies how genetics affects individual responses to drugs, particularly for those with narrow therapeutic windows (where the difference between an effective dose and a harmful dose is small).

To manage ADRs, healthcare providers may choose to withdraw the drug, reduce the dosage, provide additional treatment, or continue the current regimen without changes. It's crucial to address ADRs promptly and with appropriate medical expertise.

To improve patient safety, better reporting and assessment methods for ADRs are necessary, and pharmaceutical companies should work to minimize the adverse effects of their drugs.

Keywords: *adverse drug reaction, causalities, drug kinetics, genetic polymorphism, toxicities.*

Introduction:

Adverse drug reactions (ADRs) are more common than many people realize. They are estimated to be the fourth leading cause of death in the United States and Canada, after heart disease, cancer, and stroke. Worldwide, ADRs rank as the sixth leading cause of death. A recent meta-analysis suggested that over 180,000 Americans died from ADRs in 2008, with more than a million others injured. While these figures are debated and the true incidence of ADRs is difficult to measure, their significant impact on healthcare and drug development is clear.

The financial burden of ADRs is also substantial, with estimates ranging from $75 to $180 billion annually for adults alone. This cost far exceeds the expenses associated with treating conditions like diabetes, cardiovascular disease, or cancer, highlighting the profound impact of ADRs on healthcare systems.

About 5% of all hospital admissions are directly related to ADRs, and this rate has not improved over the past 30 years. So, what exactly are ADRs? According to the World Health Organization, an ADR is defined as "any noxious and unintended response to a drug that occurs at doses used in humans for prevention, diagnosis, or treatment." This means that an ADR can be an unexpected side effect, a harmful reaction in a non-target organ, an allergic or hypersensitive response, an unpredictable reaction, or an unexpected drug interaction.

In all these cases, ADRs represent unwanted and potentially toxic effects caused by taking a specific drug or combination of drugs. This chapter aims to explore the different types of ADRs, using specific examples to illustrate the various forms they can take and the factors that may influence their occurrence or severity.

A drug is a single active ingredient used in medicine for diagnosing, preventing, and treating diseases. However, how people respond to drugs can vary greatly from person to person, which can lead to treatment failures or unexpected side effects known as adverse drug reactions (ADRs). These reactions can significantly contribute to illness and even death in hospitalized patients.

Having a solid reporting system in hospitals can help identify and resolve drug-related issues, leading to better patient care. Spontaneous reporting is a common way to monitor ADRs, allowing healthcare professionals to spot these reactions during everyday medical practice. However, this method has its downsides, such as underreporting and a lack of information on how many patients have actually been exposed to a drug.

While some ADRs can be prevented—often due to prescription errors—others are unavoidable and may only become known after a drug is on the market. Pharmaceutical companies do their best to identify potential side effects before a drug is sold, but it's often impossible to know every possible reaction ahead of time. Therefore, effective monitoring after a drug is released is crucial. As more drugs become available and people take multiple medications, the likelihood of experiencing ADRs is likely to rise.

ADRs remain a significant issue in drug therapy, leading to increased morbidity, mortality, decreased patient compliance, and higher medical costs. This seminar paper aims to highlight the causes, clinical signs, and management strategies for ADRs, as well as to suggest areas for further research on this important topic.

Definition:

Adverse drug reaction can be defined as any noxious unintended and undesired effects of a drug that occur at doses used for prevention, diagnosis or treatment or it is an unwanted or harmful reaction following the administration of a medication or combination of medications which is suspected to be related to the medication.

Epidemiology:

Adverse drug reactions caused by immune and no immune mechanisms are a major cause of morbidity and mortality worldwide. They are the most common iatrogenic illness, complicating 5% to 15% of therapeutic drug courses. In the United States, more than 100,000 deaths are

attributed annually to serious adverse drug reactions.

Three percent to six percent of all hospital admissions are because of adverse drug reactions and 6% to 15 % of hospitalized patients (2.2 million persons in the United States in 1994) experience a serious adverse drug reaction .Epidemiologic data support the existence of specific factors that increase the risk of general adverse drug reactions, such as female, gender, or infection with human immunodeficiency virus (HIV), or herpes(Alvarez-Requejo et al.,1998) Factors associated with an increased risk for hypersensitivity drug reactions include asthma, systemic lupus erythematosus, or use of beta blockers although atopic patients do not have a higher rate of sensitization to drugs, they are at increased risk for serious allergic reactions.

Incidence and severity of ADRs vary by patient characteristics (e.g., age, sex, coexisting disorders, genetic or geographic factors) and by drug factors (e.g., type of drug, administration route, treatment duration, dosage, bioavailability). Incidence is probably higher and is more severe among the elderly

Types Of Adverse Drug Reaction:

include drug allergies (also known as hypersensitivity reactions), idiosyncratic responses, and drug intolerance. These reactions are often unpredictable and can occur even when a drug is used correctly. Since they can't be anticipated, they remain a challenge until we gather enough information about the drug and the patients using it to identify who might be at higher risk.

While pharmacovigilance—monitoring the safety of drugs—is crucial, diligent reporting of Type B ADRs is even more important. These reactions are typically recognized after a drug has been marketed and are harder to foresee.

In this section, we will explore examples of ADRs, focusing on how they affect different organ systems in the body. This will help illustrate the potential risks associated with these unpredictable reactions.

1. Drug Allergies:

The significance of drug allergies is well illustrated by penicillin. This antibiotic transformed the treatment of bacterial infections, turning potentially deadly illnesses into manageable ones with great success. Remarkably, penicillin has very few Type A adverse drug reactions (ADRs). However, it is known to cause drug allergies, which can range from mild skin itching to severe reactions like anaphylactic shock.

Other medications that can cause allergic reactions include non-steroidal anti-inflammatory drugs (NSAIDs), thiazide diuretics, sulfa drugs, anticonvulsants, barbiturates, iodine, and certain protein-based treatments like vaccines and insulin. In fact, drug allergies make up about 20% of all reported ADRs.

In this section, we will explore the different types of drug allergies, how they occur, and provide specific examples of important drug allergies.

One controversial topic in this area is known as multiple drug allergy syndrome.

This occurs when patients have allergic reactions to two or more unrelated medications. It's believed that some individuals may have a heightened tendency to develop allergic responses, whether mediated by IgE (a type of antibody) or not. This sensitivity can lead to multiple allergies, making management more complex.

2. Hypersensitivity Reactions to b-lactam Antibiotics:

Allergies to penicillin are the most commonly reported drug allergies, with about 10% of patients claiming to be allergic to it. However, a key issue is that more than 90% of these patients do not actually have the specific IgE antibodies that indicate a true immediate allergic reaction to penicillin. Additionally, many of these patients do not react to standard skin tests used to check for allergies.

The reason for the difference between what patients claim and what is classified as a true penicillin allergy isn't fully understood. This discrepancy raises important questions about diagnosing and managing penicillin allergies, as many people who believe they are allergic may not actually be at risk.

Beta-lactam antibiotics, like penicillin, are known to cause a variety of allergic adverse drug reactions (ADRs). However, many of these reactions don't fit neatly into the traditional classifications of allergic reactions, such as those described by Gell and Coombs. Instead, they often involve both IgE-mediated reactions and T-cell mediated responses, leading to immediate, late, and delayed hypersensitivity reactions.

For the rest of this chapter, we will focus specifically on IgE-related allergic reactions because we have a better understanding of how these reactions occur with beta-lactam antibiotics. This will help us explore the mechanisms behind these allergies and their implications for patient care.

3. Multiple Drug Allergy Syndrome

The term "multiple drug allergy syndrome" refers to patients who have had allergic reactions to two or more unrelated medications, and it's a topic of debate among researchers. One theory suggests that if a person develops an allergy to one drug, they may be more likely to develop allergies to other drugs due to an overall tendency to have allergic reactions, whether mediated by IgE or not.

However, there are limited studies that definitively support the existence of this syndrome or explain the mechanisms behind it. In fact, some studies contradict the idea of multiple drug allergy syndrome. For example, research by Khoury and colleagues found that patients who were allergic to penicillin were actually less likely to react to other antibiotics. This indicates that the relationship between drug allergies may not be as straightforward as initially thought.

4. Mechanisms of Allergic Responses

the most widely accepted idea about how drug-induced allergies develop is that small drug molecules, called haptens, must first attach to a larger protein to trigger an immune response. This process, known as

haptenation, forms a new complex that the immune system can recognize. For penicillins, this usually leads to immediate allergic reactions associated with the presence of IgE antibodies.

Interestingly, the method of administering beta-lactam antibiotics seems to influence the type of allergic response. While not conclusively proven in detailed studies, there is substantial evidence suggesting that injections (parental routes) are more likely to cause Type 1 allergies and anaphylaxis compared to oral administration.

There's limited data on whether genetics play a role in susceptibility to antibiotic allergies. Few studies have been conducted on this topic, and those that exist often rely on patient histories rather than rigorous testing. Additionally, many of these studies do not distinguish between IgE-mediated and non-IgE-mediated reactions. Some suggest that individuals with a family history of drug allergies may have an increased immune response to drug-protein complexes formed during treatment.

While it is well established that beta-lactam antibiotics commonly cause drug allergies, other classes of drugs can also lead to allergic reactions. For example, sulfonamide allergies occur in about 20% to 30% of AIDS patients, often presenting as skin rashes. Some severe reactions, like Stevens-Johnson syndrome, may result from certain metabolites of sulfonamides.

Given the diverse history and uses of sulfa-based compounds, there is concern about potential cross-allergic reactions in patients allergic to sulfonamides. However, to date, no significant increase in allergic reactions to non-antibiotic sulfa compounds has been observed in these patients. Further research is needed to better understand these issues.

5. Nonallergic Type

Nonallergic Type ADRs refer to drug reactions that do not involve the immune system but can still cause adverse effects in patients. Unlike allergic reactions, which are typically mediated by the immune response (like IgE antibodies), nonallergic reactions can arise from several mechanisms, including:

1. **Pharmacological Effects**: These reactions occur due to the drug's intended effects or side effects. For instance, an opioid might cause drowsiness or constipation as a predictable pharmacological effect.
2. **Toxic Effects**: Some drugs can have toxic effects at certain doses, leading to organ damage or other serious issues. For example, high doses of acetaminophen can lead to liver toxicity.
3. **Drug Interactions**: When multiple medications are taken, they can interact in ways that cause adverse effects. For example, certain antibiotics can reduce the effectiveness of oral contraceptives.
4. **Idiosyncratic Reactions**: These are unusual reactions that occur in a small number of patients and are not well understood. They can be influenced by genetic factors or other individual characteristics but do not involve the immune system.
5. **Overdose**: Taking too much of a medication, whether intentionally or accidentally, can lead to severe adverse reactions that are not related to allergy.

Understanding nonallergic Type ADRs is crucial for improving patient safety and ensuring effective drug therapy. These reactions can often be anticipated and managed through careful prescribing practices and patient education.

6. Idiosyncratic Hepatotoxicity

Idiosyncratic hepatotoxicity is a rare but serious type of adverse drug reaction that primarily affects humans. This form of toxicity results from a complex series of events triggered by specific drugs, leading to liver damage. Several key factors influence this type of reaction, including the drug itself, how long a person is exposed to it, and individual environmental and genetic factors.

The properties of drugs that are most likely to cause idiosyncratic liver toxicity include:

- **Formation of Reactive Metabolites**: Some drugs are converted into highly reactive forms that can damage liver cells.
- **Metabolism by Cytochrome P450 Enzymes**: These enzymes play a significant role in how drugs are processed in the liver.
- **Presence of P450 Inducers**: Certain substances can increase the activity of P450 enzymes, potentially leading to more reactive metabolites.
- **Clinically Significant Drug Interactions**: Drugs that affect liver function can interact with other medications, increasing the risk of toxicity.



Annual report for national adverse drug reaction monitoring

Diagnosis and attribution of causality

Diagnosing an adverse drug reaction is a crucial part of evaluating a patient's overall health. When a patient is on medications, it's important to consider the possibility that their symptoms could be due to an ADR. Here's how the process typically unfolds:

1. **Identify All Medications**: First, determine what the patient is taking. This includes:
    - Prescription medications
    - Over-the-counter drugs
    - Herbal or traditional remedies
    - Recreational drugs or substances of abuse
    - Long-term medications that the patient might forget, like oral contraceptives
2. **Assess Possible Causation**: Once you know what the patient is taking, the next step is to evaluate whether any of these medications could be

causing the observed effects. This can be challenging, especially if the patient is on multiple medications or if symptoms could also be linked to other health issues.

3. **Establish Timing**: Timing is a key factor in determining if there's a link between the drug and the reaction. Consider the following:
    - Does the reaction occur or worsen when the drug reaches a stable dose or when that dose is increased?
    - Does the reaction improve or resolve when the drug dose is lowered or discontinued?
    - If you suspect a drug interaction, does the timing of adding or stopping the interacting drug make sense?
    - For allergic reactions, has the patient been exposed to the drug before? While prior exposure strengthens the case for an allergy, it doesn't rule out a reaction.
    - If the effect is a congenital abnormality, was the drug taken during the critical period of development?
    - If the effect is a tumor, was there enough time for it to develop based on known tumor growth patterns?

By carefully considering these factors, healthcare providers can better determine whether an ADR is likely and which medication may be responsible. This thorough approach is essential for ensuring patient safety and effective treatment.

When a patient experiences an adverse reaction after taking a medication, the first step is to withdraw that drug immediately. Following this withdrawal, it's crucial to monitor the patient's condition closely. If the patient's symptoms do not improve, the next likely culprit medication should be considered for withdrawal.

If the patient's condition still isn't stabilizing, alternative treatments for the underlying condition can be initiated to address the basic disease while managing the adverse drug reaction (ADR). Should the situation remain unchanged, it may be necessary to reassess and repeat the process by identifying and withdrawing the next suspected medication.

In cases where multiple drugs have been stopped, a careful reintroduction of medications may be warranted. Begin with the drug least likely to cause issues and consider using a lower dose if the reaction appears to be related to the dosage.

If a critical medication is implicated in causing the ADR, finding a suitable alternative is essential. However, it is important to be cautious about potential cross-sensitivity with similar medications.

While addressing the ADR, providing symptomatic relief is also important. For instance, patients undergoing treatment for cancer may require medications to manage nausea and vomiting. Throughout this process, healthcare providers should aim to simplify management by avoiding the introduction of unnecessary medications, maintaining clear treatment goals, limiting

the duration of symptomatic treatments, and regularly reviewing the patient's progress.

By adhering to these guidelines, healthcare providers can effectively manage adverse drug reactions while ensuring that patients continue to receive the necessary treatments for their conditions.

When a serious adverse drug reaction (ADR) is suspected, rapid action is crucial, especially in emergencies like anaphylactic shock. In such cases, immediate treatment and the withdrawal of all medications may be necessary. However, if some medications are essential for the patient's health, a careful reintroduction of those drugs may be needed after stabilization.

Here's how to approach the situation:

1. **Assess the Situation**: Use clinical judgment to weigh the benefits and risks of continuing or stopping medications. This involves considering the severity of the reaction and whether there are alternative treatments that could be used instead.
2. **Identify the Culprit**: If it's clear which medication may be causing the reaction, you need to decide whether it's critical to continue using it. Are there effective substitutes available that are less likely to cause the same reaction?
3. **Withdrawal Strategy**: If multiple medications could be causing the issue, start by withdrawing non-essential medications first. This should ideally be done one at a time to monitor for any changes.
4. **Dose Adjustment**: If the ADR seems related to the dosage, consider reducing the dose rather than stopping the medication altogether. Many healthcare providers might withdraw a drug when they suspect an interaction instead of adjusting the dosage appropriately.

By carefully evaluating these factors, healthcare providers can manage ADRs effectively while still addressing the patient's overall treatment needs.

When a patient experiences an adverse reaction after taking a medication, the first step is to withdraw that drug immediately. Following this withdrawal, it's crucial to monitor the patient's condition closely. If the patient's symptoms do not improve, the next likely culprit medication should be considered for withdrawal.

If the patient's condition still isn't stabilizing, alternative treatments for the underlying condition can be initiated to address the basic disease while managing the adverse drug reaction (ADR). Should the situation remain unchanged, it may be necessary to reassess and repeat the process by identifying and withdrawing the next suspected medication.

In cases where multiple drugs have been stopped, a careful reintroduction of medications may be warranted. Begin with the drug least likely to cause issues and consider using a lower dose if the reaction appears to be related to the dosage.

If a critical medication is implicated in causing the ADR, finding a suitable alternative is essential. However, it is

important to be cautious about potential cross-sensitivity with similar medications.

While addressing the ADR, providing symptomatic relief is also important. For instance, patients undergoing treatment for cancer may require medications to manage nausea and vomiting. Throughout this process, healthcare providers should aim to simplify management by avoiding the introduction of unnecessary medications, maintaining clear treatment goals, limiting the duration of symptomatic treatments, and regularly reviewing the patient's progress.

By adhering to these guidelines, healthcare providers can effectively manage adverse drug reactions while ensuring that patients continue to receive the necessary treatments for their conditions



Management of Adverse Drug reaction

Future developments

Future developments The work of the WHO monitoring programme in Uppsala is described in detail elsewhere.21 The programme also supports the European Pharmacovigilance Research Group, which has allowed regulators and drug-safety specialists from a variety of European countries to come together to plan coordinated drug-safety exercises.

Initiatives like these may pave the way for much more logical development and investigation of drug safety signals worldwide. Among the developments planned for the WHO programme are:

An extension of the method of Bayesian artificial neural networks for the analysis of large amounts of data, in the hope of detecting hitherto unrevealed risk factors for the development of drug-related ailments

Improvements in the classification systems of traditional herbal remedies

Cooperation with organisations interested in developing early signals of significance, including the International Society for Pharmacoepidemiology, which is specifically interested in the science of pharmacovigilance, and the Council for International Organizations of Medical Sciences, which is pivotal in bringing interested parties together to mount various collaborative projects.

Clinical pharmacology has a very exciting future, because of possibilities of interfering with disease processes at ever more basic and specific levels. Knowledge of the human genome will allow us to predict susceptibility to an increasing number of diseases, and drug-induced disease will also be better understood as we gain knowledge of genetic influences on drug pharmacokinetics and pharmacodynamics: we already use phenotyping and genotyping to predict some drug problems related to drug metabolism.

Further genomic developments will allow us to develop predictive tests for the actions of drugs, including adverse drug reactions, holding out the possibility of more accurate tailoring of therapy to the individual. As we accumulate more and more information on drug responses, we must not lose sight of the sobering fact that about half the cases of drug-related injury are from potentially avoidable adverse drug reactions.

Tools and Innovations for Managing Adverse Drug Reactions (ADRs)

Managing adverse drug reactions (ADRs) has significantly advanced through various tools and innovations aimed at improving patient safety and treatment outcomes. One of the primary systems in place is pharmacovigilance, which utilizes database reporting mechanisms, such as the FDA's Adverse Event Reporting System (FAERS), to collect and analyze data on ADRs. This system is enhanced by signal detection algorithms that can identify patterns within large datasets, allowing for proactive monitoring of potential drug safety issues.

Electronic health records (EHRs) also play a crucial role by integrating patients' medication histories, including documented ADRs, which aids healthcare providers in making informed prescribing decisions. EHRs can issue real-time alerts about potential drug interactions or previous allergic reactions, enhancing patient safety.

Pharmacogenomics represents another significant innovation, as genetic testing can predict how individual patients will respond to certain medications. This personalized approach helps reduce the risk of ADRs by guiding dosing and medication selection based on a patient's genetic profile.

Mobile health applications are increasingly utilized for ADR management. These apps

enable patients to log their symptoms and medication use, providing valuable data for healthcare providers. Additionally, medication reminder tools help ensure patients adhere to their treatment regimens, minimizing the chances of ADRs due to missed doses.

Tools and Innovations

Applications of Adverse Drug Reaction (ADR) Management

The management of adverse drug reactions (ADRs) has several critical applications that enhance patient safety and optimize therapeutic outcomes. Here are key areas where ADR management plays an essential role:

1. **Clinical Practice**:

- **Patient Safety**: Monitoring and managing ADRs helps healthcare providers ensure patient safety, reducing the incidence of harmful drug effects.
- **Informed Prescribing**: Clinicians use ADR information to make better prescribing decisions, considering patients' histories of drug reactions and potential interactions.

2. **Pharmacovigilance**:

- **Surveillance Systems**: ADR reporting systems, like the FDA's FAERS, collect data to identify and analyze patterns in drug-related adverse events, leading to improved drug safety profiles.
- **Risk Assessment**: Ongoing surveillance allows for the evaluation of risk versus benefit for medications in real-world settings, leading to timely updates on drug safety information.

3. **Regulatory Affairs**:

- **Drug Approval Process**: ADR data from clinical trials inform regulatory bodies about the safety of new drugs before they are approved for market use.
- **Post-Marketing Studies**: Regulatory agencies mandate post-marketing studies to monitor ADRs once drugs are available to the public, ensuring continuous safety evaluation.

4. **Pharmacogenomics**:

- **Personalized Medicine**: By assessing genetic factors that influence drug metabolism, healthcare providers can predict individual responses to medications, minimizing the risk of ADRs and tailoring treatments to the patient.

5. **Public Health**:

- **Awareness Campaigns**: Public health initiatives educate patients and healthcare professionals about the signs and risks of ADRs, promoting prompt reporting and management.
- **Data-Driven Policies**: Aggregated ADR data can inform public health policies, contributing to safer drug use and improved health outcomes at the population level.

6. **Research and Development**:

- **Drug Development**: Understanding ADRs informs the design of new drugs, guiding researchers in developing safer therapeutic options.
- **Clinical Trials**: Knowledge of ADRs helps in designing more effective clinical trials, ensuring that potential adverse effects are monitored and reported accurately.

7. **Education and Training**:

- **Healthcare Provider Training**: Ongoing education about ADRs enhances the ability of healthcare professionals to recognize, manage, and report these reactions effectively.

- **Patient Education**: Empowering patients with knowledge about potential ADRs encourages them to participate in their care actively, improving adherence and safety.

8. **Technology Integration**:

- **Electronic Health Records (EHRs)**: EHRs integrate ADR data, allowing healthcare providers to track patient histories and receive alerts about potential adverse reactions in real time.

- **Mobile Health Applications**: Apps enable patients to report ADRs and track their medication usage, facilitating communication with healthcare providers and enhancing safety monitoring.

By applying these strategies across various domains, ADR management significantly contributes to improving drug safety, optimizing therapeutic outcomes, and enhancing overall patient care.

Conclusion

Adverse drug reactions (ADRs) are often linked to differences in how drugs are processed in the body (pharmacokinetics) and how they affect the body (pharmacodynamics). These reactions can vary widely based on a person's health, environment, and other factors. While there's been a lot of research into what influences the likelihood of experiencing an ADR, there's still a need for better ways to combine this knowledge with practical care to protect patients who need medication.

It is present a significant challenge in healthcare, impacting patient safety and treatment outcomes. Understanding the various types, mechanisms, and factors that contribute to ADRs is crucial for effective management and prevention. While research continues to shed light on the complexities of ADRs, it is essential to integrate this knowledge into clinical practice

Reference

1) *Aston, H. (1984). Benzodiazepine withdrawal: an unfinished story. Br. med. J. 288; 1135-1140.*
2) *Bateman, D. N., Rawlins, M. D. & Simpson, J. M. (1985). Extrapyramidal reactions with metoclopra mide. Br. med. J., 291, 930-932.*
3) *Bateman, D. N., Rawlins, M. D. & Simpson, J. M. (1986). Extrapyramidal reactions to prochlorpera zine and haloperidol in the United Kingdom. Quart. J. Med., 59, 549-556.*
4) *Committee on the Safety of Medicines (1986a). CSM Update: Annual Review of Yellow Card Reports 1985. Br. med. J. 293, 641-708.*
5) *Goetz, C. G., Weiner, W. J., Nausieda, P. A. & Klawans, H. L. (1982). Tardive dyskinesia: pharmacology and clinical implications. Clin. Neuropharmacology, 5, 3-22.*
6) *WHO. International monitoring of adverse reactions to drugs: adverse reaction terminology. WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden, 1992.*
7) *Zopf Y. Risk factors associated with adverse drug reactions following hospital admission: a prospective analysis of 907 patients in two German university hospitals. Drug Safety 2008; 31: 789-798.*
8) *Word Health Organization. International drug monitoring: the role of the hospital. Geneva, Switzerland: word health*

organization;1966. technical report series no.425.

9) *Dr. Ramesh KG, Dr. Parloop AB, Dr. Mahesh DB. Elements of clinical pharmacy, 4th edn:2008-2009, B.S. Shah prakashan; page no-109-114.*
10) *Bennett PN, Brown MJ. Clinical Pharmacology. Tenth edition. Churchill Livingstone, Edinburgh, 2008.*
11) *Laurence D, Carpenter J. A dictionary of pharmacology and allied topics, 2nd edn. Amsterdam: Elsevier, 1998: 8–9.*
12) *Grahame-Smith DG, Aronson JK. Adverse drug reactions. In: The Oxford textbook of clinical pharmacology and drug therapy. Oxford: Oxford University Press, 1984: 132–57.*
13) *Simmons C, Georgeson EM, Hill RC (1998) Adverse drug reactions: can we reduce the risk? Hospital Pharmacy 33, 1568–1576.*
14) *Wiffen P, Gill M, Edwards J, Moore A (2002) Adverse drug reactions in hospital patients. A sys tematic review of the prospective and retrospective studies. Bandolier Extra June, 1–16.*
15) *Edwards IR, Aronson JK (2000) Adverse drug reac tions: definitions, diagnosis and management. Lancet 356, 1255–1259.*
16) *British Medical Association, Royal Pharmaceutical Society of Great Britain. (2005) British National Formulary. London: BMA, RPS, (No 49).*
17) *Leape LL, Brennan TA, Laird N et al. (1991) The nature of adverse events in hospitalized patients. The New England Journal of Medicine 324, 377–384.*